Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 33.83 1.23% 0.41
FATE closed up 1.23 percent on Friday, August 7, 2020, on 52 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical FATE trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
Crossed Above 20 DMA Bullish 1.23%
Crossed Above 50 DMA Bullish 1.23%
Expansion Pivot Buy Setup Bullish Swing Setup 1.23%
Pocket Pivot Bullish Swing Setup 1.23%
Bollinger Band Squeeze Range Contraction 1.23%
Wide Range Bar Range Expansion 1.23%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Biology Stem Cells Hematologic Malignancies Orphan Diseases Cord Blood Adult Stem Cell Induced Stem Cells Lysosomal Storage Disorders Muscular Dystrophies

Is FATE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 38.52
52 Week Low 12.59
Average Volume 971,273
200-Day Moving Average 25.73
50-Day Moving Average 33.06
20-Day Moving Average 33.04
10-Day Moving Average 32.40
Average True Range 1.89
ADX 14.53
+DI 26.28
-DI 15.64
Chandelier Exit (Long, 3 ATRs ) 32.83
Chandelier Exit (Short, 3 ATRs ) 35.83
Upper Bollinger Band 35.38
Lower Bollinger Band 30.70
Percent B (%b) 0.67
BandWidth 14.16
MACD Line -0.18
MACD Signal Line -0.24
MACD Histogram 0.0593
Fundamentals Value
Market Cap 1.4 Billion
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -35.24
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.01
Resistance 3 (R3) 36.04 35.34 35.64
Resistance 2 (R2) 35.34 34.79 35.33 35.52
Resistance 1 (R1) 34.59 34.45 34.97 34.56 35.40
Pivot Point 33.89 33.89 34.08 33.88 33.89
Support 1 (S1) 33.14 33.34 33.52 33.10 32.26
Support 2 (S2) 32.44 33.00 32.43 32.14
Support 3 (S3) 31.69 32.44 32.02
Support 4 (S4) 31.65